 VANCOUVER and MINNEAPOLIS, May 13, 2021 GLOBE NEWSWIRE -- via NewMediaWire -- Neovasc Inc. Neovasc or the Company NASDAQ, TSX: NVCN today announced that it will sponsor a symposium presenting the latest long-term clinical data on the ReducerTM Reducer, highlighting its easy integration into current cardiovascular and microvascular disease treatments. The symposium titled, Latest clinical evidence and practical aspects to start Reducer therapy in your center, will be presented at the 2021 EuroPCR, taking place digitally from May 18-20, 2021. EuroPCR is a leading opportunity for cardiologists to exchange ideas and latest best practices. 